Citadel Advisors’s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) ECTE Stock Holding History

Citadel Advisors’s Portfolio ECTE Stock Details ECTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-32,550	Closed	-$42K	–	8261
2016 Q2	$42K	Buy	32,550 +4,596	+16%	+$7.36K	﹤0.01%	6452
2016 Q1	$38K	Buy	+27,954	New	+$33.3K	﹤0.01%	6325
2015 Q4	–	Sell	-14,613	Closed	-$23K	–	9579
2015 Q3	$23K	Buy	+14,613	New	+$23.3K	﹤0.01%	8078
2014 Q4	–	Sell	-24,356	Closed	-$20K	–	8941
2014 Q3	$20K	Buy	+24,356	New	+$43.9K	﹤0.01%	7446

Other funds holding ECTE

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Citadel Advisors's ECTE Position: Q3 2016 in Review

Citadel Advisors sold out of ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) (ECTE) in Q3 2016, closing a stake of 32,550 shares — an estimated $42K sold.

Citadel Advisors first reported a position in ECTE in Q3 2014 and held it in 4 quarters. The position peaked at $42K in Q2 2016. 2 funds tracked by Wall St. Rank hold ECTE as of Q3 2016.

Citadel Advisors reported no remaining ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position as of Q3 2016 after selling out during the quarter.
Citadel Advisors sold 32,550 ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) shares in Q3 2016, an estimated $42K.
Citadel Advisors first reported a position in ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) in Q3 2014 and held it in 4 quarters.
Citadel Advisors's ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position peaked at $42K in Q2 2016.
2 funds tracked by Wall St. Rank held ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) as of Q3 2016.

Based on Citadel Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.